Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

II-VI Q3 Profit Declines - Quick Facts

II-VI Inc. (IIVI: Quote) posted third-quarter net earnings attributed to the company of $13.99 million or $0.22 per share compared to $23.12 million or $0.36 per share last year.

Revenues for the quarter rose 2% to $132.59 million from $130 million in the prior year.

Analysts polled by Thomson Reuters expected the company to report earnings of $0.25 per share on revenues of $134.28 million for the quarter. Analysts' estimates typically exclude special items.

Francis Kramer, president and chief executive officer, commented, "We achieved record bookings in our third fiscal quarter, the result of strengthening product demand across the majority of the markets we serve. Product orders in the Infrared Optics segment and at Photop Technologies, Inc. (Photop) were robust -- up 13% and 17%, respectively, from the year-ago quarter and up 35% and 60%, respectively, from the quarter ended December 31, 2011. As a result, our backlog increased $13 million during the quarter and now totals $174 million. Consequently, we have better visibility in the near-term outlook."

Click here to receive FREE breaking news email alerts for II-VI Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Proctor and Gamble (PG) has sold two of its soap brands to European consumer products giant Unilever (UN). Cincinnati-based P&G says the sale includes the global Camay brand, the Zest brand outside of North America and its Talisman manufacturing plant in Mexico. The plant employs approximately... Dish Network is no longer carrying Fox News in yet another dispute for the television provider. Fox News, which changed the face of cable news with its ardent advocacy of conservative issues, went dark Sunday, replaced on Dish by The Blaze, Glen Beck's new right-leaning channel. Fox Business channel... Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.